Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.
暂无分享,去创建一个
Robert L. Judson | Robert L Judson | I. Yeh | Shanshan Liu | B. Bastian | T. Prow | J. Benhamida | A. Shain | J. North | L. Pincus | B. Ruben | N. Joseph | Richard Yu | Jamal Benhamida
[1] Robert L. Judson,et al. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. , 2018, Cancer cell.
[2] O. Boyman,et al. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. , 2017, Cell reports.
[3] B. Bastian,et al. From melanocytes to melanomas , 2016, Nature Reviews Cancer.
[4] Eric Talevich,et al. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..
[5] R. Dummer,et al. The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.
[6] Nam Huh,et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination , 2015, Proceedings of the National Academy of Sciences.
[7] Nam Huh,et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway , 2015, Nature Genetics.
[8] S. Ariyan,et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.
[9] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[10] R. Dummer,et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors , 2015, Nature Communications.
[11] Li Ding,et al. Clonal Architectures and Driver Mutations in Metastatic Melanomas , 2014, PloS one.
[12] Anne-Mette K. Hein,et al. Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue , 2014, PloS one.
[13] Iwei Yeh,et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.
[14] Jonathan R. Pollack,et al. The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers , 2013, PloS one.
[15] Jamie K Teer,et al. Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma , 2012, BMC Genomics.
[16] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[17] Matthew J. Davis,et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.
[18] M. Meyerson,et al. Abstract 3178: Can DNA from archived formalin-fixed paraffin embedded (FFPE) cancer tissues be used for somatic mutation analysis in next generation sequencing , 2012 .
[19] C. Eng,et al. Lifetime Cancer Risks in Individuals with Germline PTEN Mutations , 2012, Clinical Cancer Research.
[20] C. V. Jongeneel,et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.
[21] Ralf Herwig,et al. Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity , 2011, BMC Medical Genomics.
[22] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[23] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[24] J. O'Brien,et al. Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.
[25] Scott L Pomeroy,et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.
[26] B. Taylor,et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.
[27] N. Dumaz,et al. c-Kit mutants require hypoxia-inducible factor 1α to transform melanocytes , 2010, Oncogene.
[28] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[30] U. Rapp,et al. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. , 2008, The Journal of investigative dermatology.
[31] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[32] Ajay N. Jain,et al. Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.
[33] L. Chin,et al. The INK4a/ARF locus and melanoma , 2003, Oncogene.
[34] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[35] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[36] P. Kleihues,et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.